Literature DB >> 17106922

Mechanisms and significance of liver steatosis in hepatitis C virus infection.

Francesco Negro1.   

Abstract

The pathogenesis of liver damage associated with chronic hepatitis C virus (HCV) infection is thought to be largely immunomediated. However, some frequent histopathological features, such as steatosis, suggest a direct cytopathic effect of HCV. The direct responsibility of HCV in the pathogenesis of steatosis is shown by: (1) the association with HCV genotype 3 infection, suggesting that some viral sequences are involved in the intracellular accumulation of lipids; (2) the correlation between severity of steatosis and HCV replication levels; (3) association between response to treatment and disappearance of steatosis. Experimental studies have shown that the nucleocapsid protein of HCV (core protein) is capable and sufficient to induce lipid accumulation in hepatocytes. Moreover, the observation that chronic hepatitis C patients have reduced serum levels of ApoB suggests an interference with the very-low density lipoprotein (VLDL) assembly, although other mechanisms are possible. In patients with sustained virological response induced by antiviral therapy, such levels are normalized. Other observations suggest that the pathogenesis of steatosis in chronic hepatitis C is not solely due to HCV. The origin of the mild steatosis observed in most patients may be metabolic, since its severity correlates with body mass index and insulin resistance. Most studies have shown a correlation between presence and/or severity of steatosis and fibrosis stage, but it is unclear whether this effect is direct or mediated by the associated insulin resistance, increased susceptibility to apoptosis, or by inflammatory cytokines. Finally, steatosis negatively influences the rate of response to antiviral treatment, as confirmed by large clinical trials. Management of steatosis in chronic hepatitis C requires knowledge of its pathogenesis and may involve both life-style changes and pharmacological interventions, although the latter remain largely experimental.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17106922      PMCID: PMC4087428          DOI: 10.3748/wjg.v12.i42.6756

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  92 in total

1.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice.

Authors:  K Moriya; H Yotsuyanagi; Y Shintani; H Fujie; K Ishibashi; Y Matsuura; T Miyamura; K Koike
Journal:  J Gen Virol       Date:  1997-07       Impact factor: 3.891

2.  Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype.

Authors:  S Mihm; A Fayyazi; H Hartmann; G Ramadori
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets.

Authors:  G Barba; F Harper; T Harada; M Kohara; S Goulinet; Y Matsuura; G Eder; Z Schaff; M J Chapman; T Miyamura; C Bréchot
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.

Authors:  M Ziol; J T Nhieu; F Roudot-Thoraval; J M Métreau; Y Deugnier; D Dhumeaux; E S Zafrani
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

5.  Higher incidence of diabetes in liver transplant recipients with hepatitis C.

Authors:  H Knobler; A Stagnaro-Green; S Wallenstein; M Schwartz; S H Roman
Journal:  J Clin Gastroenterol       Date:  1998-01       Impact factor: 3.062

6.  Host- and disease-specific factors affecting steatosis in chronic hepatitis C.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  J Hepatol       Date:  1998-08       Impact factor: 25.083

7.  Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population.

Authors:  M E Allison; T Wreghitt; C R Palmer; G J Alexander
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

8.  Two cases from the spectrum of nonalcoholic steatohepatitis.

Authors:  M Abdelmalek; J Ludwig; K D Lindor
Journal:  J Clin Gastroenterol       Date:  1995-03       Impact factor: 3.062

9.  High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests.

Authors:  H Gray; T Wreghitt; I M Stratton; G J Alexander; R C Turner; S O'Rahilly
Journal:  Diabet Med       Date:  1995-03       Impact factor: 4.359

10.  Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.

Authors:  E Larrea; N Garcia; C Qian; M P Civeira; J Prieto
Journal:  Hepatology       Date:  1996-02       Impact factor: 17.425

View more
  39 in total

Review 1.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

4.  Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection.

Authors:  Eva Askar; Giuliano Ramadori; Sabine Mihm
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

5.  Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?

Authors:  Aliya Qayyum; Daryl M Chen; Richard S Breiman; Antonio C Westphalen; Benjamin M Yeh; Kirk D Jones; Ying Lu; Fergus V Coakley; Peter W Callen
Journal:  Clin Imaging       Date:  2009 Mar-Apr       Impact factor: 1.605

6.  Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus.

Authors:  Kohichiroh Yasui; Yuichi Harano; Hironori Mitsuyoshi; Kazuhiro Tsuji; Mio Endo; Tomoaki Nakajima; Masahito Minami; Yoshito Itoh; Yoh Zen; Yasuni Nakanuma; Toshikazu Yoshikawa; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

7.  Hepatitis C virus induces the cannabinoid receptor 1.

Authors:  David van der Poorten; Mahsa Shahidi; Enoch Tay; Jayshree Sesha; Kayla Tran; Duncan McLeod; Jane S Milliken; Vikki Ho; Lionel W Hebbard; Mark W Douglas; Jacob George
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

8.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21

9.  Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus.

Authors:  John Paul Pezacki; Selena M Sagan; Angela M Tonary; Yanouchka Rouleau; Sylvie Bélanger; Lubica Supekova; Andrew I Su
Journal:  BMC Chem Biol       Date:  2009-01-16

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.